Tag: NASDAQ:LPTN

Finance

Shining on Major News: Vale S.A. (NYSE:VALE), Bank of America Corporation (NYSE:BAC), CubeSmart (NYSE:CUBE), Lpath Inc. (NASDAQ:LPTN), Papa John’s International Inc. (NASDAQ:PZZA)

Citigroup Inc. lowered shares of Vale SA (NASDAQ:VALE) from a neutral rating to a sell rating in a report released on Tuesday. Vale S.A. (NYSE:VALE) belongs to Basic Materials sector. Its net profit margin is -5.90% and weekly performance is -6.50%. On last trading day company shares ended up $8.92. Vale S.A. (NYSE:VALE) distance from 50-day simple moving average (SMA50) is -20.00%. David Sobotka, Bank … Continue reading Shining on Major News: Vale S.A. (NYSE:VALE), Bank of America Corporation (NYSE:BAC), CubeSmart (NYSE:CUBE), Lpath Inc. (NASDAQ:LPTN), Papa John’s International Inc. (NASDAQ:PZZA)

Kevin Long
Finance

New Lows: Novogen (NASDAQ:NVGN), Zafgen Inc (NASDAQ:ZFGN), Lpath (NASDAQ:LPTN), Ambit Biosciences (NASDAQ:AMBI)

Novogen Limited (ADR) (NASDAQ:NVGN) and CanTx Inc., on June 17, 2014 announced that the proof-of-concept pre-clinical studies were successful. Novogen and its joint venture company CanTx Inc. also gave confirmation of the potency of Intra-Peritoneal Trx-1, their experimental drug. Novogen Limited (ADR) (NASDAQ:NVGN) stock performance was -1.75% in last session and finished the day at $3.37. Traded volume was 19,720.00million shares in the last session … Continue reading New Lows: Novogen (NASDAQ:NVGN), Zafgen Inc (NASDAQ:ZFGN), Lpath (NASDAQ:LPTN), Ambit Biosciences (NASDAQ:AMBI)

Jayne Crisman
Finance

Biotech Unusual Volume: Zalicus Inc (NASDAQ:ZLCS), ImmunoGen (NASDAQ:IMGN), Transition Therapeutics (NASDAQ:TTHI), Lpath (NASDAQ:LPTN)

Zalicus Inc (NASDAQ:ZLCS) will merge with Epirus Biopharmaceuticals in an all-stock transaction. Zalicus will be known as Epirus and will operate under the latter company’s management team led by Amit Munshi as president and CEO. Current Zalicus Inc (NASDAQ:ZLCS) stockholders will own approximately 19% of the company. The merger will create a publicly-traded company listed on the NASDAQ. Zalicus Inc (NASDAQ:ZLCS) stock performance was 31.07% … Continue reading Biotech Unusual Volume: Zalicus Inc (NASDAQ:ZLCS), ImmunoGen (NASDAQ:IMGN), Transition Therapeutics (NASDAQ:TTHI), Lpath (NASDAQ:LPTN)

Colin Pettis
BioTech

Biotech Unusual Volume Stocks: Arca Biopharma (NASDAQ:ABIO), Biota Pharmaceuticals (NASDAQ:BOTA), Lpath (NASDAQ:LPTN), La Jolla Pharmaceutical (NASDAQ:LJPC)

Arca Biopharma Inc (NASDAQ:ABIO) focuses on developing genetically targeted therapies for cardiovascular disease. Its lead product candidate, Gencaro, is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the prevention of atrial fibrillation in patients with heart failure and reduced left ventricular ejection fraction. Arca Biopharma Inc (NASDAQ:ABIO) stock performance was 11.34% in last session and finished the day at $2.16. Traded volume … Continue reading Biotech Unusual Volume Stocks: Arca Biopharma (NASDAQ:ABIO), Biota Pharmaceuticals (NASDAQ:BOTA), Lpath (NASDAQ:LPTN), La Jolla Pharmaceutical (NASDAQ:LJPC)

Mark DeFrance
Finance

Hot Biotech Gainers: Sangamo Biosciences (NASDAQ:SGMO), CEL-SCI Corporation (NYSEMKT:CVM), Agios Pharmaceuticals (NASDAQ:AGIO), Lpath (NASDAQ:LPTN)

HIV usually infects blood cells through a protein on their surface, a “docking station” called CCR5. A California company, Sangamo BioSciences Inc. (NASDAQ:SGMO), makes a treatment that can knock out a gene that makes CCR5. Sangamo Biosciences, Inc. (NASDAQ:SGMO) stock performance was 17.08% in last session and finished the day at $22.96. Traded volume was 11.36 million shares in the last session and the average … Continue reading Hot Biotech Gainers: Sangamo Biosciences (NASDAQ:SGMO), CEL-SCI Corporation (NYSEMKT:CVM), Agios Pharmaceuticals (NASDAQ:AGIO), Lpath (NASDAQ:LPTN)

Chris Lewis